Latest news with #CharlesMartin
The Independent
6 days ago
- Sport
- The Independent
CARVILL'S NOTES: Looking Too Hard for a Hero?
The cry for a heavyweight champion is so loud that it often drowns out the need for common sense and rationality. Nine years ago, I was in the Scholars Lounge in Rome. It was not a place of learning, but one of the city's numerous 'Irish' bars. I was on my way back from the International Journalism Festival in Perugia and had stopped for two nights in the Immortal City. Catch all the latest boxing action on DAZN It was the weekend that Anthony Joshua challenged 'Prince' Charles Martin for the IBF heavyweight title. Joshua, 15-0 (15), was coming into the ring after beating Dillian Whyte, his somewhat rival, in seven rounds. Martin, 23-0-1 (21), was defending his title for the first time, having beaten Vyacheslav Glazkov for it two-and-a-half months earlier. There was a young couple sat on the same table with me. We were not together as a group, but we were all interested in watching the fight. 'What do you think of Martin?' asked the man. 'Not much.' 'So Joshua wins?' I shrugged. 'I guess. But the problem is who he fights afterwards. Fifteen fights, knocking out all those guys to get here – what happens when he starts having mandatories against those who can really fight back?' Joshua stopped Martin in two rounds that night. He defended against Dominic Breazeale and Eric Molina in subsequent bouts, then stopped Wladimir Klitschko in eleven. But it was after that the sheen began to come off. The underrated Carlos Takam pushed Joshua hard, who would go onto look less than inspired in subsequent bouts against Joseph Parker and Alexander Povetkin. Then Andy Ruiz knocked him out in seven. Even though Joshua would win the rematch, he looked almost hesitant. A win over Kubrat Pulev inspired few. Then there were the losses to Oleksandr Usyk and Dubois. Even with the run of victories of lesser opponents, it seems that Joshua either left something behind in the ring along the way or it was never developed in the first place. I lean towards the latter, and that is why I have been thinking that thought a lot this week, because we are running up to Saturday when the undefeated Moses Itauma, 12-0 (10), is set to meet Dillian Whyte, 31-3 (21), in a twelve-round bout in Riyadh, Saudi Arabia. It is a fight that either moves Itauma into true contention – where is already being lined up in some quarters to be the next, and final, dance partner of Oleksandr Usyk – or relegates him back down a few levels. And yet I feel that this fight may be coming too soon for Itauma. He has only fought twelve times in the professional ranks. Ten of his victories have come by stoppage, with only two of his wins going past the second round. A twelve-fight professional record is still the record of an amateur learning the ropes of the trade. When Anthony Joshua was 12-0, his next opponent was Kevin Johnson. At that time, Johnson was on the long downslope of his career, having slipped into the role of gatekeeper. Other heavyweight champions, in their thirteenth fights, fought opponents of a similar level. For Lennox Lewis, it was Mike Acey, 11-4-1. For Mike Tyson, it was Conroy Nelson, 15-7-2. For Wladimir Klitschko, it was Marcos Gonzalez, 18-11-1. Brother Vitali fought Anthony Willis, 16-6, in his thirteenth pro fight. Tyson Fury went in against Zack Page, 21-32-2, at the same point. I doubt Whyte is at the stage of his career that those fighters were at. He may have last had a significant fight in 2022 (against Fury), but he is has stopped three men in the years since – all of whom would be better learning fights for Itauma, still a relative novice. The other fighter I have been thinking of this weekend has been David Price, who was 15-0 (13) when he went out to face Tony Thompson, 36-3 (24), in Liverpool. Thompson stopped him in two and, five months later, repeated the same trick in five. At the time of their first bout, Thompson was only one fight away from challenging Wladimir Klitschko for the world heavyweight title. Again, Price had been rushed into it. And he paid the price with two losses and a career that was derailed to finish at 25-7 (20). I thought then that Price had been set to fight Tony Thompson too soon. Such was the hubris of those around him that they made that fight. And that same hubris led them immediately to the rematch. I fear that same hubris is being played out again. And on that note: · There is an effort right now in Germany to revive the nation's boxing scene. When I arrived here over a decade ago, the Klitschkos were filling arenas and stadiums throughout Europe. Arthur Abraham was also headlining arenas, as were Marco Huck and Felix Sturm. It was not unusual for fights on German soil to have 40,000 spectators. But those days now seem long past, with three of those five fighters now retired and events being lucky to have 5,000 spectators. Not long ago, I heard a rumour that Abraham and Sturm had discussed fighting one another, but their individual asking prices of €500,000 have so far been deemed 'too high'. Even nostalgia, it seems, has its limits. · If normal life is stranger than fiction, then boxing is often stranger than normal life. One of the most-interesting characters I've met through my time in boxing is a guy called 'Jack'. That is not his real name, but I know him through a former boxer, a once European champion, who met 'Jack' through a gym that 'Jack' trained in. The boxer and 'Jack' became friends. 'Jack', who is a high-priced lawyer in London, helped the boxer with some contractual battles with his former promoter. He is also a white-collar boxer. Not long ago, I was watching a Vice documentary on bareknuckle boxing and saw 'Jack' sitting in the crowd at a fight in the Midlands. I sent him a message, asking if it was him. He confirmed it was and said, 'Yeah, I'm thinking of having one or two bareknuckle fights.' I would not put it past him. · Speaking of Kevin Johnson, the former heavyweight contender has disappeared off the radar. I last saw him fighting outside a bar in Hamburg, Germany (not as sleazy as it sounds). He had a couple of more fights here but seemed to be content to have slipped into the role of journeyman, seemingly losing all of them by decision. I may not have spoken to him in a while, but it seems that he has joined up with a foreign army, taking as his name that of the nation's president. Indeed, if normal life is stranger than fiction, the boxing is stranger than normal life. Watch the very best boxing with a DAZN subscription DAZN is the home of combat sports, broadcasting over 185 fights a year from the world's best promoters, including Matchroom, Queensberry, Golden Boy, Misfits, PFL, BKFC, GLORY and more. An Annual Saver subscription is a one-off cost of £119.99 / $224.99 (for 12 months access), that's just 64p / $1.21 per fight. There is also a Monthly Flex Pass option (cancel any time) at £24.99 / $29.99 per month. A subscription includes weekly magazine shows, comprehensive fight library, exclusive interviews, behind-the-scenes documentaries, and podcasts and vodcasts.
Associated Press
08-05-2025
- Business
- Associated Press
CB Scientific, Inc. (CBSC) Announces Corporate Name Change to Cardiac Biotech Solutions, Inc.
LAS VEGAS, NV / ACCESS Newswire / May 8, 2025 / Cardiac Biotech Solutions, Inc. (OTC PINK:CBSC) ('CBSC' or the 'Company'), a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products, announced today that the Company's name was changed to 'Cardiac Biotech Solutions, Inc.' effective May 7, 2025, following completion of the review of the Company's application to change its name by the Financial Industry Regulatory Authority (FINRA) and approval of the name change at the annual meeting of the Company's shareholders held on March 14, 2024. The name change will not impact the Company's current CBSC ticker symbol, nor will it affect the Company's assigned CUSIP number, the unique nine-digit identification number assigned to financial securities in the United States and Canada. 'We believe the name Cardiac Biotech Solutions more accurately reflects our core mission of advancing heart health,' said Charles Martin, Chief Executive Officer of CBSC. 'With FDA clearance now secured for our next-generation MyCardia AT event monitor, we are excited to move forward with a successful product launch in partnership with our established international distribution partners across Southeast Asia, Hong Kong, and Macau.' Additionally, the regulatory submission process for the MyCardia AT has resumed in collaboration with the Company's Chinese manufacturing partner, Shenzhen Pump, and representatives from the National Medical Products Administration (NMPA) in China, progressing toward market clearance. Concurrently, regulatory submission has also begun in Canada through our distribution partner, Your Heart Protector Corp., aiming to secure market approval across the Canadian healthcare landscape. The MyCardia AT cardiac event monitor is designed to enhance the remote cardiac monitoring experience with its lightweight, easy-to-wear form factor and flexible options for transmitting event recordings. The device seamlessly integrates with the AWS Cloud-based MyCardia portal, as well as the widely adopted MyCardia mobile applications for iOS and Android. This ensures a cohesive and optimized user experience across global markets via smartphones and the MyCardia app on Apple, Google, or WeChat platforms. As additional new developments occur, Cardiac Biotech Solutions, Inc. plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed. About Cardiac Biotech Solutions, Inc. Cardiac Biotech Solutions, Inc., through its international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our electrocardiogram (EKG) devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians. Company Contact Information: Telephone: (888) 225-0870 Investor Inquiries: [email protected] Follow CBSC: X, Facebook, Instagram, LinkedIn, YouTube, and Newsletter This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words 'plan,' 'expect,' 'believe,' and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions. SOURCE: Cardiac Biotech Solutions, Inc. press release
Yahoo
21-02-2025
- Sport
- Yahoo
Rapid City's Martin Recalled To AHL
The Rapid City Rush announced on Friday that defenseman Charles Martin has been recalled by the Calgary Wranglers of the American Hockey League. This isn't the first time the 26-year-old blueliner has been recalled to the Calgary Flames' AHL affiliate. He received a call-up on New Year's Day and made his AHL debut before being reassigned back to the Rush Jan. 6. Martin appeared in 16 consecutive games with Rapid City before this latest call-up to the Wranglers. He's certainly earned it, having scored nine points, including three multi-point performances, during those 16 games. The Blainville, Que. Native has spent his entire ECHL career with the Rush, which totals 97 games dating back to March of 2023. He was named an alternate captain prior to this season. Martin will join the Wranglers in southern California ahead of a three-game road trip against Coachella Valley, Ontario and San Diego. It's no coincidence that the Rush have been hot at the same time as Martin. The club carries a six-game winning streak into West Valley City for a three-game series with the Utah Grizzlies starting Friday. Rapid City's last win was a wild 6-4 triumph over the Maine Mariners at the Monument Ice Arena Feb. 16. Trevor Janicke scored the game-tying and game-winning goals to preserve the victory, which improved the club's record to 18-22-8. The current win streak equals a previous one in March of 2023, when the Rush defeated a combination of Wichita, Tulsa, and Fort Wayne. Puck drop for Friday's game against the Grizzlies is scheduled for 7:10 Pm MT.
